ADVI Health Accelerates Insights with Monthly Medicare Data
ADVI Health now has access to 100% of Medicare Parts A, B, and D research files with monthly availability – enabling faster, more responsive evidence generation and market insights.
What This Means for Our Clients and Partners
- Timelier Insights: Near real-time visibility into utilization and outcomes.
- Faster Evidence Generation: Accelerated health economics and outcomes research (HEOR), real-world evidence (RWE), and market access analytics aligned with evolving payer and policy needs.
- Quicker Value Demonstration: Shorter data-driven evidence cycles.
- Real-Time Market Awareness: Ongoing visibility into treatment patterns, competitive dynamics, and policy-driven shifts.
Why it Matters
In today’s evolving healthcare landscape, timing is everything. With monthly data access, ADVI enables faster, more responsive evidence generation, helping clients and partners stay ahead of change, demonstrate value sooner, and act with confidence.
Turning Data into Actionable Insights
ADVI combines timely Centers for Medicare and Medicaid Services (CMS) data with deep policy, HEOR, and market access expertise to uncover emerging trends and translate complex healthcare data into strategic insights.
ADVI Advantage
ADVI leverages high-frequency data and advanced analytics to deliver precise, timely, and actionable insights— strengthening our position as a leading partner for organizations seeking strategic, evidence-driven decision support in policy impacts, market access, and HEOR.
Medicare Drug Price Negotiation
Early Insights from Medicare Drug Price Negotiation
ADVI’s analysis of H1 2025 and H1 2026 data data reveals how the first year of Medicare drug price negotiation is affecting patient costs, prescription spending, and Part D plan design.
Patients Saw Minimal Decreases in Out-of-Pocket Expenses
Patient expenses decreased an average of only $11.71 per prescription, which is a 9% decrease from 2025 to 2026 and aligns more with the average 2024 OOP.

Data based on 2025 and 2026 Q1 patient out-of-pocket costs across all IPAY drugs, weighted by claims volume
Out-of-Pocket Costs Increased for Some MFP Drugs
For some MFP drugs, out-of-pocket patient costs increased:

Data represents 2025 and 2026 Q1 and Q2 averages for non-low-income out-of-pocket patient costs by drug
Total Spending and Claim Volume Decreased Across MFP Drugs
Total spending and claim volume across all MFP drugs decreased from 2025 to 2026
Total prescription costs
Total claims



Data across all MFP drugs for January through June of 2024, 2025, and 2026
Total spending and claim volume Increased Across All Part D Claims
Total spending and claim volume increased across all Part D claims from 2024 to 2026
Total prescription costs
Total claims



Data across all MFP drugs for January through June of 2024, 2025, and 2026
$0 Deductible Part D Plan Enrollment Dropped Significantly
The proportion of enrollees in $0 deductible Part D plans dropped significantly from 2025 to 2026

Ready to Turn Data into Action?
Partner with ADVI Health to Turn Data into Impact—Faster
CEO insights
Related articles
Real analysis from people who’ve been there
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.





